




**Supplementary Figure 1.** Screening and randomization. From the 4,257 men who were assessed for eligibility, 3,835 were excluded: 3,789 were seronegative on recruitment, 22 withdrew from study, and 24 did not return for follow-up visit. A total of 422 men formed the primary cohort (68 received oral zinc+vitamin C, 67 oral hydroxychloroquine, 99 oral ivermectin, 107 povidone-iodine throat spray, and 81 oral vitamin C).




# Supplementary Figure 2.



Supplementary Figure 3

**A**



**B**

